{"id":"NCT00910520","sponsor":"Allergan","briefTitle":"Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-09","primaryCompletion":"2011-08","completion":"2011-08","firstPosted":"2009-06-01","resultsPosted":"2013-03-05","lastUpdate":"2013-03-05"},"enrollment":548,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Overactive Bladder"],"interventions":[{"type":"BIOLOGICAL","name":"onabotulinumtoxinA","otherNames":["BOTOXÂ®","botulinum toxin Type A"]},{"type":"DRUG","name":"normal saline","otherNames":[]}],"arms":[{"label":"onabotulinumtoxinA","type":"EXPERIMENTAL"},{"label":"placebo/onabotulinumtoxinA","type":"OTHER"}],"summary":"The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.","primaryOutcome":{"measure":"Change From Baseline in Number of Daily Episodes of Urinary Incontinence","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"onabotulinumtoxinA","deltaMin":5.52,"sd":3.753},{"arm":"Placebo/onabotulinumtoxinA","deltaMin":5.7,"sd":3.858}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":7,"countries":["United States","Belgium","Czechia","Germany","Poland","Russia","United Kingdom"]},"refs":{"pmids":["26231052","24754838","23608668"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":274},"commonTop":["Urinary tract infection","Dysuria","Bacteriuria","Urinary retention"]}}